Phospholipase A2 with weak enzymatic activity, which inhibits partially inhibits thrombin enzymatic activity (Ki=73 nM), completely inhibits thrombin-induced platelet aggregation and retards fibrin clot formation (IC(50)=0.2 nM) (PubMed:19622365). May exert this anticoagulant effect through a non-enzymatic mechanism (PubMed:19622365). Does not exert detectable effects on both the intrinsic and extrinsic pathways of the coagulation cascade (up to 50 nM) (PubMed:19622365). Does not hydrolyze either fibrinogen or thrombin (PubMed:19622365). Does not have impact on already formed fibrin clot (PubMed:19622365). Is not toxic to PC12 tumor cells (up to 15 uM), but evokes neurite outgrowth in these cells (1 uM) (PubMed:19622365). Has not effect on ADP-induced platelet aggregation (PubMed:19622365). a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) Binds 1 Ca(2+) ion. Monomer. Expressed by the venom gland. The active site (His-25) is not easily accessible for modification by 4-bromophenacyl bromide (BPB). Belongs to the phospholipase A2 family. Group I subfamily. D49 sub-subfamily.